MEDIWOUND LTD.

(MDWD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about MEDIWOUND LTD.
05/18Wells Fargo Adjusts MediWound's Price Target to $8 From $7, Keeps Overweight Rating
MT
05/17SECTOR UPDATE : Health Care Stocks Rising Ahead of Tuesday Close
MT
05/17SECTOR UPDATE : Health Care Stocks Firming with Broader Market Gains
MT
05/17TRANSCRIPT : MediWound Ltd., Q1 2022 Earnings Call, May 17, 2022
CI
05/17MediWound Appoints Ofer Gonen as CEO
MT
05/17MEDIWOUND : Q1 Earnings Snapshot
AQ
05/17MediWound Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/17MediWound Announces CEO Transition
GL
05/17MediWound Announces CEO Transition
GL
05/17MediWound Reports First Quarter 2022 Financial Results
GL
05/17Earnings Flash (MDWD) MEDIWOUND Reports Q1 Loss $-0.12, vs. Street Est of $-0.11
MT
05/17Earnings Flash (MDWD) MEDIWOUND Reports Q1 Revenue $4.4M, vs. Street Est of $4.29M
MT
05/17MediWound Ltd. Announces Executive Changes
CI
05/17Mediwound Ltd. Appoints Sharon Malka to the Company's Board of Directors
CI
05/12MediWound Says Mid-Stage Trial of EscharEx for Debridement of Chronic Wounds Meet Prima..
MT
05/12MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debrid..
GL
05/12MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debrid..
AQ
05/12MediWound Ltd. Announces Positive Results from U.S. Phase 2 Clinical Study of Escharex®..
CI
05/12MediWound Shares Up After EscharEx Study Met Primary Endpoint
DJ
05/10MediWound to Report First Quarter Financial Results and Host a Conference Call and Webc..
GL
05/10MediWound to Report First Quarter Financial Results and Host a Conference Call and Webc..
GL
04/13MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Ad..
AQ
04/12MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Ad..
AQ
03/30MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SA..
AQ
03/29MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SA..
AQ
03/22MEDIWOUND : Announces Exercise of Over-Allotment Option - Form 6-K
PU
03/22MediWound Announces Exercise of Over-Allotment Option
GL
03/21Aegis Capital Adjusts MediWound Price Target to $7 From $9, Maintains Buy Rating
MT
03/21MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement..
GL
03/21MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement..
CI
03/17TRANSCRIPT : MediWound Ltd., Q4 2021 Earnings Call, Mar 17, 2022
CI
03/17MediWound Q4 Loss Widens, Revenue Declines
MT
03/17MEDIWOUND : Q4 Earnings Snapshot
AQ
03/17MEDIWOUND : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 6-K
PU
03/17Earnings Flash (MDWD) MEDIWOUND Reports Q4 Revenue $5.5M, vs. Street Est of $5.54M
MT
03/17MediWound Reports Fourth Quarter and Full Year 2021 Financial Results
GL
03/17MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/17MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
CI
03/10MediWound Announces Closing of Public Offering of Ordinary Shares
AQ
03/10MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Confe..
AQ
03/03MEDIWOUND : Announces Pricing of Public Offering of Ordinary Shares - Form 6-K
PU
03/03MediWound Prices $10 Million Share Offering At Discount; Stock Falls
MT
03/03MediWound Announces Pricing of Public Offering of Ordinary Shares
AQ
03/02MEDIWOUND : Announces Proposed Public Offering of Ordinary Shares - Form 6-K
PU
03/02MediWound Proposes Underwritten Public Offering of Ordinary Shares
MT
03/02MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
GL
03/01MediWound to Present at Upcoming Investor Conferences in March
GL
02/28MEDIWOUND : Presentation - January 2022
PU
02/17MediWound Awarded a U.S. Department of Defense Research Grant for the Development of Ne..
GL
02/17U.S. Department of Defense Awards Defense Research Grant to Mediwound Ltd. for the Deve..
CI
02/14MediWound to Present at Upcoming Investor Conferences in February
GL
02/14MediWound to Present at Upcoming Investor Conferences in February
GL
02/10MediWound Secures Additional $9 Million in BARDA Funding
MT
02/10MEDIWOUND : Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA ..
PU
02/10MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA..
AQ
02/10MediWound Ltd. announced that it has received $9 million in funding from Biomedical Adv..
CI
01/24Health Care Stocks Declining This Afternoon
MT
01/24Health Care Stocks Dragged Lower in Broad-Based Equities Selloff
MT
01/24Wall Street Set for Losses Amid Ukraine Crisis
MT
01/24Health Care Stocks Retreat Premarket Monday
MT
01/24Top Premarket Gainers
MT
01/24MediWound Discloses 'Positive' Data From Phase 2 Study of Leg Ulcer Treatment
MT
01/24MEDIWOUND : Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for..
PU
01/24MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx fo..
GL
01/24Mediwound Announces Positive Topline Results from Its U.S. Phase 2 Trial of Escharex fo..
CI
2021MediWound Says Phase 2 Study of EscharEx Treatment for Chronic Wounds Delivers Positive..
MT
2021MEDIWOUND : Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of Es..
PU
2021MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of E..
AQ
2021MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of E..
CI
2021MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study, Topl..
AQ
2021MediWound Completes Enrollment of Phase 2 Study of EscharEx; Shares Rise Pre-Bell
MT
2021MEDIWOUND : Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study - Form..
PU
2021MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
AQ
2021MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
CI
2021EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid
GL
1  2  3  4  5  6Next
Upcoming event on MEDIWOUND LTD.